Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (53)	6/24/2003 5:51:39 PM
From: tuck	Respond to of 295

ESPR has been on quite a tear lately, so I imagine the Street is pricing in good results in this trial: >>ANN ARBOR, Mich.--(BUSINESS WIRE)--June 24, 2003--Esperion Therapeutics, Inc. (Nasdaq:ESPR - News), a biopharmaceutical company focused on discovering and developing HDL-targeted therapies for the treatment of cardiovascular disease, will hold a conference call at 8:30 a.m. (EDT) on Thursday, June 26, 2003 following the announcement of initial results from a Phase II clinical trial of Esperion's ETC-216 (AIM) product candidate. In addition to reviewing the initial ETC-216 study results, Esperion will provide an update on the clinical development of its two other biopharmaceutical product candidates. Roger S. Newton, Ph.D., President and Chief Executive Officer, will host the call and will be joined by Timothy M. Mayleben, Chief Operating Officer and Chief Financial Officer, and Adeoye Y. Olukotun, M.D., M.P.H., F.A.C.C., Senior Vice President of Clinical and Regulatory Affairs and Chief Medical Officer. Following their prepared comments, Dr. Newton, Mr. Mayleben and Dr. Olukotun will be available for a brief question and answer session. Investors and others are invited to join the call live via telephone or on the Internet. What: Esperion Conference Call to Review Initial ETC-216 Phase II Trial Results When: Thursday, June 26, 2003 at 8:30 a.m. (EDT) Via Telephone: From the U.S. and Canada, dial (800) 299-6183 From other locations, dial (617) 801-9713 Please give password "Esperion" when prompted Via Internet: Visit esperion.com, click on the Investor Relations link and then the Calendar link shortly before 8:30 a.m. (EDT) A replay of the Esperion conference call will be available beginning at 11:00 a.m. (EDT) on June 26, 2003, until 11:59 p.m. (EDT), July 3, 2003. To access the replay from the U.S. and Canada, dial (888) 286-8010 and enter passcode #53305324. From all other locations, dial (617) 801-6888 and enter passcode #53305324. To access the replay via the Internet, visit esperion.com, click on the Investor Relations link and then click on the Audio/Visual Archives link. << snip Incidentally, the stock has recently become optionable, allowing many ways to play the event. Cheers, Tuck

To: Miljenko Zuanic who wrote (53)	7/8/2003 5:04:12 AM
From: nigel bates	Read Replies (1) \| Respond to of 295

AELA trial still ongoing, but this hardly inspires confidence - Québec City, Canada July 7, 2003 Æterna Laboratories Inc. (TSE: AEL, Nasdaq :AELA) announced today that it has entered into an agreement with a syndicate of underwriters led by RBC Capital Markets and including National Bank Financial Inc., Paradigm Capital Inc., Desjardins Securities Inc. and Loewen, Ondaatje, McCutcheon Ltd., to issue and sell 4.5 million subordinate voting shares of Æterna at a price of $7.90 (Canadian) per share. The Company has also granted the underwriters an option to purchase up to an additional 1 million subordinate voting shares. Gross proceeds of this transaction will be $35.6 million assuming that the underwriters’ option is not exercised. The transaction is subject to the receipt of all necessary regulatory and stock exchange approvals. Closing is expected on or about July 24, 2003. The proceeds from this financing will be used by AEterna to continue the active development of its lead antiangiogenic product, Neovastat, in oncology with phase III clinical trials in renal cell carcinoma and non-small cell lung cancer and for the continued broadening of clinical and commercial opportunities not only of Neovastat, but of the many other products in Aeterna’s pipeline. The proceeds will be also used for the Company’s growth strategy based on strategic alliances and acquisition of new technologies, as well as for general corporate purposes...